连续性肾脏替代治疗中抗凝剂的应用现状及发展方向

中国药物警戒 ›› 2013, Vol. 10 ›› Issue (11): 658-662.

连续性肾脏替代治疗中抗凝剂的应用现状及发展方向

赵颖琦,高娜,阴凯^*

华北电网有限公司北京电力医院重症医学科,北京 100073

收稿日期:2013-09-12 修回日期:2016-03-09 出版日期:2013-11-08 发布日期:2016-03-09
通讯作者: 阴凯,男,主任医师,危重症医学。E-mail:dryinkai@sina.com
作者简介:赵颖琦,女,医学博士,危重症医学。

Application Status and Development Direction of Anticoagulant in Continuous Renal Replacement Therapy

ZHAO Ying-qi ,GAO Na ,YIN Kai^*

Intensive Care Unit, Beijing Electric Power Hospital, North China Grid Company Limited, Beijing 100073, China

Received:2013-09-12 Revised:2016-03-09 Online:2013-11-08 Published:2016-03-09

摘要/Abstract

摘要： 连续性肾脏替代治疗（CRRT）技术是目前危重症医学上重要的器官支持手段之一。由于其治疗时间较间歇性血液透析明显延长,因此对抗凝的要求更高。本文综述了目前CRRT 中常用的抗凝剂的应用现状。普通肝素（UFH）抗凝仍然是目前国内CRRT 最常用的抗凝方法之一,但其不良反应需引起重视,主要包括：出血发生率高,易发生肝素诱导性血小板减少症（HIT）,肝素抵抗等。低分子肝素（LMWH）与肝素比较,引发出血并发症几率更低,但剂量不易控制,监测手段复杂,限制了其广泛应用。局部枸橼酸抗凝（RCA）易于使用,而且已被证明能延长滤器寿命并且无全身抗凝危险,是CRRT 重要且最有发展力的抗凝方法之一。近年来RCA 的标准化方案及预冲配方成为枸橼酸抗凝领域新兴的研究热点。

关键词: 连续性肾脏替代治疗, 抗凝剂, 不良反应

Abstract: Continuous renal replacement therapy(CRRT) technique is one of the important means of organ support in critical care medicine. Due to its treatment time is significantly longer than intermittent hemodialysi, the requirement for anticoagulation is even more. This paper reviews the current application status of commonly used anticoagulant in CRRT. At present, unfractionated heparin(UFH) remains one of the most commonly used anticoagulant method for domestic CRRT, but its adverse reactions should be paid attention, mainly including high incidence rate of bleeding, heparin-induced thrombocytopenia(HIT), heparin resistance, etc. Compared with heparin, the rate of low molecular weight heparins(LMWH) caused bleeding complications is lower, but the dose is difficult to control and the monitoring method is complex, which limits its wide use. Regional citrate anticoagulation(RCA) is one of the important and promising anticoagulant Methods for CRRT because it's easy to use, and has been testified to extend the life of the filter without systemic anticoagulation danger. In recent years, standardized solution of RCA and preflush formula become a hot spot in the field of citrate anticoagulation.

Key words: continuous renal replacement therapy, anticoagulant, adverse reaction

中图分类号:

R973.2

赵颖琦,高娜,阴凯 . 连续性肾脏替代治疗中抗凝剂的应用现状及发展方向[J]. 中国药物警戒, 2013, 10(11): 658-662.

ZHAO Ying-qi ,GAO Na ,YIN Kai . Application Status and Development Direction of Anticoagulant in Continuous Renal Replacement Therapy [J]. Chinese Journal of Pharmacovigilance, 2013, 10(11): 658-662.

参考文献

[1] Hochart H, Jenkins P V, Preston R J, et al. Concentration-depentent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood[J]. Thromb Haemost, 2008,99(3): 570-575.
[2] van de Wetering J, Westendorp R G, van de Hoeven J G, et al.Heparin use in continuous renal replacement procedures: the steuggle between filter coagulation and patient hemorrhage[J]. J Am Soc Nephrol, 1996, 7(1): 145-150.
[3] 马驰骋,芦昌慧,刘爱军,等. 在肝素抗凝的连续肾脏替代治疗中活化部分凝血活酶时间适宜时间的研究[J]. 中国全科医学,2010,13（6）：1993－1996.
[4] Oudenmans-Van Straaten HM,Wester J P, de PontAC, et al. Anticoagulation strategies in continuous renal replacememt therapy:can the choice be evidence based[J].Intensive Care Med, 2006, 32(2): 188-202.
[5] Carr JA, Silverman N. The heparin-protamine interaction. A review[J].J Cardiovase Surg(Torino), 1999, 40(5): 659-666.
[6] 叶朝阳,赵久石,陆石.血液透析管路通路技术及临床应用[Ｍ].上海：复旦大学出版社,2010：212.
[7] 黄馥菡,施向东.100例尿毒症血液透析患者肝素诱导的血小板减少症发病率及临床特点[J].浙江实用医学,2011,16（4）：250-261.
[8] PosadasMA,Hahn D, SchleuterW, et al. Thrombocytopenia associatedwith dialysis treatments[J].Hemodial Int,2011,15(3): 416-423.
[9] 高亚,赵永强,王书杰. 肝素制剂应用患者中血小板减少症的发病率及病因分析[J].中日友好医院学报,2010,24（4）：198-201.
[10] Tsirigotis P, Mantzios G, Makris F, et al. Bilateral renal artery thrombosis due to heparin-induced thrombocytopenia-thrombosis syndrome. Successful treatment with longterm application of lepirudin[J]. Ulster Med, 2006, 75(1): 88-90.
[11] Kannan, Meganathana, Ahmad, et al. Funcional characterization of antibodies against heparin-platelet factor 4 complex in heparininduced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers[J]. Blood Coagulation & fibrinolysis, 2008,19(6): 471-475.
[12] 卿国忠,尹建亚,张克娜,等. 血液净化并发肝素诱导的血小板减少症临床观察[J].中南医学科学杂志,2013,41（1）：54-57.
[13] Hirsh J, Warkenin T E, Shaughnessy S G, et al. Heparin and low-molecular-weight heparin:mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety[J]. Chest, 2001, 119(1):64S-94S.
[14] Cohen J R, Sarfati I, Birnbaum E, et al. The inactivation of antithrombinIII byserumelastaseinpatients withsurgical infections [J].Am Surg, 1990, 56(11): 665-667.
[15] GrittersM, Borgdorff P, GrootemanMP, et al. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility[J].Nephrol Dial Transplant, 2008, 23(9): 2911-2917.
[16] Oudemans-Van Straaten H M, van Schilfgaared M, Molenaar P J,et al. Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltrarion rates[J].Crit Care,2009, 13(6): R193.